Lamassu BioTech, Cleveland, OH (2026)

01/12/2026

Our CEO, Gabi Hanna, MD, recently sat down with RBV Quarterly to discuss what makes a successful leader. As Dr. Hanna shared, “In biotech, you are always racing against the clock. Patent life starts on day one, and every delay reduces your chances of success. Market windows open and close quickly, and when you miss them, the opportunity disappears, regardless of the quality of your science. Time isn’t a preference to optimize — it is a decisive constraint that shapes
everything we do.”

🔗 in the comments.

01/06/2026

🎗️ Sarcomas: rare, but deeply impactful.

📊 In 2025, the U.S. will see an estimated ~13,520 new cases of soft-tissue sarcoma.

⏳ Outcomes remain strongly stage-dependent:
•83% 5-year survival when localized.
• Only 17% 5-year survival once metastatic.

🔎 Although sarcomas represent just ~1% of adult cancers, they account for ~15% of pediatric cancers — underscoring the urgent unmet need.

At Lamassu Biotech, our novel therapy SA53 targets the MDM2–p53 axis, with the goal of advancing precision oncology in sarcoma and beyond.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development.
📚 Source: American Cancer Society, 2025.

12/30/2025

🐈 𝐂𝐚𝐭𝐬 𝐡𝐢𝐝𝐞 𝐢𝐥𝐥𝐧𝐞𝐬𝐬 𝐰𝐞𝐥𝐥 — 𝐚𝐧𝐝 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐢𝐬 𝐧𝐨 𝐞𝐱𝐜𝐞𝐩𝐭𝐢𝐨𝐧.

Subtle symptoms like loss of appetite, lethargy, and dehydration often go unnoticed, delaying diagnosis. The vagueness of these signs, paired with limited treatment options in veterinary medicine, highlights a significant unmet need.

At Lamassu Pets, our work on 𝐑𝐀𝐁𝐈 𝟕𝟔𝟕 𝐮𝐧𝐝𝐞𝐫𝐬𝐜𝐨𝐫𝐞𝐬 𝐭𝐡𝐢𝐬 𝐩𝐚𝐫𝐚𝐥𝐥𝐞𝐥 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐚𝐜𝐫𝐨𝐬𝐬 𝐛𝐨𝐭𝐡 𝐡𝐮𝐦𝐚𝐧 𝐚𝐧𝐝 𝐯𝐞𝐭𝐞𝐫𝐢𝐧𝐚𝐫𝐲 𝐡𝐞𝐚𝐥𝐭𝐡.

⚠️ Disclaimer: RABI 767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Animal Biome blog by Dr. Tonya Cooksey, DVM (Aug 15, 2025)

12/23/2025

Lamassu BioTech's leadership team, CEO Gabi Hanna MD. and CSO Greg Palmer, PhD, will be on the ground for the J.P. Morgan Healthcare Conference this January to share a year of breakthrough progress and clinical momentum. Following highly encouraging data, we are ready to discuss the future of our two lead programs:

🔬 SA53 | Precision Oncology
We are advancing our MDM2 inhibitor program for p53-wildtype tumors. Ongoing Phase 1/2 clinical data continues to show a favorable safety profile across multiple targeted cancer types, reinforcing our confidence in this genetically targeted approach.

🐾 RABI-767 | Acute Pancreatitis
We are scaling our "One Health" approach to address this significant unmet need. We are particularly excited to advance our LamassuPet animal health program—bringing RABI-767 to canines while simultaneously progressing the human clinical pathway alongside our partners.

We look forward to connecting with industry leaders and investors to discuss how we can accelerate these life-saving therapies for both human and animal patients.

12/23/2025

🎯 A target doesn’t equal a therapy.

In oncology, identifying a molecular target is only the first step. Turning that insight into a safe and effective treatment requires more than just “hitting the target.” It requires a framework of hypotheses that guide every stage of drug design.

At Lamassu Biotech, our work with SA53 — an investigational therapy targeting the MDM2–p53 axis — is built on three pillars:
✔ Biomarkers → defining which patients are most likely to benefit, and how to measure that benefit in trials.
✔ Resistance pathways → anticipating how tumors may adapt, so strategies can evolve before resistance takes hold.
✔ Safety from day 0 → ensuring that every step of development considers tolerability and risk management alongside efficacy.

This disciplined approach is how we move from basic science toward precision oncology.

The p53 pathway is one of the most studied in cancer biology — yet translating that knowledge into therapies has proven challenging. We believe that carefully integrating biomarker science, resistance biology, and safety data can shift that equation.

At Lamassu, our mission is to rethink the MDM2–p53 axis and build therapies designed with patients in mind, from day one.

12/16/2025

🐾 Did you know that dogs can also develop pancreatitis?

Certain breeds — like Miniature Schnauzers and Terriers — face an especially high risk due to factors including genetics, high-fat diets, and metabolic predispositions.

Just as in humans, veterinary medicine lacks approved drugs to treat the underlying disease. Supportive care is the only option.
At Lamassu Pets, our work with RABI-767 highlights the parallel unmet needs in both human and veterinary health.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Mansfield C. J Small Anim Pract. 2012.

12/11/2025

🧬 𝐓𝐡𝐞 𝐩𝟓𝟑–𝐌𝐃𝐌𝟐 𝐚𝐱𝐢𝐬 𝐢𝐧 𝟗𝟎 𝐬𝐞𝐜𝐨𝐧𝐝𝐬.

- 𝐩𝟓𝟑: the genome’s guard
- 𝐌𝐃𝐌𝟐: the silencer. Too much MDM2 → imbalance and cancer progression
- 𝐒𝐀𝟓𝟑: Lamassu’s investigational approach to restore balance

👉 Did you know? 𝐓𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐌𝐃𝐌𝟐 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝟐𝟎𝟎𝟎𝐬 — but challenges remain. That’s why innovation is still needed. At Lamassu Biotech, we are building on decades of research to advance the field.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development.

11/25/2025

🩺 𝐀𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 (𝐀𝐏) 𝐢𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐚 𝐩𝐚𝐢𝐧𝐟𝐮𝐥 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 – 𝐢𝐭 𝐢𝐬 𝐚 𝐠𝐥𝐨𝐛𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡 𝐛𝐮𝐫𝐝𝐞𝐧.

Every year, hundreds of thousands of patients are hospitalized with AP, making it 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐜𝐚𝐮𝐬𝐞𝐬 𝐨𝐟 𝐠𝐚𝐬𝐭𝐫𝐨𝐢𝐧𝐭𝐞𝐬𝐭𝐢𝐧𝐚𝐥 𝐚𝐝𝐦𝐢𝐬𝐬𝐢𝐨𝐧𝐬 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞.

While many cases are mild and self-limited, 𝐬𝐞𝐯𝐞𝐫𝐞 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐢𝐬 𝐚 𝐥𝐢𝐟𝐞-𝐭𝐡𝐫𝐞𝐚𝐭𝐞𝐧𝐢𝐧𝐠 𝐞𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐲:
⚠️ Mortality can reach 𝟐𝟎–𝟒𝟎%, driven by organ failure and systemic complications.

Despite decades of research, 𝐭𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐭𝐢𝐥𝐥 𝐧𝐨 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐝𝐫𝐮𝐠𝐬 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝 that directly target the underlying mechanisms of this disease. Current treatment remains supportive care only – fluids, pain control, and vigilant monitoring.

At Lamassu BioTech, we believe patients and clinicians deserve better options. That is why we are investigating 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕, our novel small molecule designed to intervene at the root of AP’s pathophysiology. Follow us for updates on our pipeline.

𝘋𝘪𝘴𝘤𝘭𝘢𝘪𝘮𝘦𝘳: 𝘙𝘈𝘉𝘐-767 𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭. 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘝𝘪𝘴𝘪𝘵 𝘓𝘢𝘮𝘢𝘴𝘴𝘶𝘉𝘪𝘰𝘵𝘦𝘤𝘩.𝘤𝘰𝘮 𝘧𝘰𝘳 𝘶𝘱𝘥𝘢𝘵𝘦𝘴 𝘯𝘰𝘷𝘦𝘭 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘶𝘯𝘥𝘦𝘳 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵.

11/17/2025

𝐓𝐡𝐞 𝐩𝟓𝟑–𝐌𝐃𝐌𝟐 𝐚𝐱𝐢𝐬 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲’𝐬 𝐦𝐨𝐬𝐭 𝐝𝐲𝐧𝐚𝐦𝐢𝐜 𝐟𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬.

In the past 6 months, new research has reshaped the field:
1️⃣ Emerging 𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲𝐬.
2️⃣ Refined 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬.
3️⃣ Expanding relevance 𝐛𝐞𝐲𝐨𝐧𝐝 𝐬𝐚𝐫𝐜𝐨𝐦𝐚.

At Lamassu Biotech, 𝐰𝐞 𝐚𝐫𝐞 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐒𝐀𝟓𝟑 to build on this evolving evidence — with the goal of unlocking precision oncology for patients who need it most.

📚 Recent reviews also highlight 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐨𝐫𝐢𝐚𝐥 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐰𝐢𝐭𝐡 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 as a promising path forward.

11/12/2025

🩺 𝐀𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐢𝐬 𝐚 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐞𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐲 𝐭𝐡𝐚𝐭 𝐜𝐚𝐧’𝐭 𝐛𝐞 𝐢𝐠𝐧𝐨𝐫𝐞𝐝.

Every year in the U.S., ~𝟐𝟎𝟎,𝟎𝟎𝟎–𝟐𝟕𝟓,𝟎𝟎𝟎 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 are hospitalized with this sudden, life-threatening condition. Yet today, the standard of care remains 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐨𝐧𝐥𝐲 — there are no approved drugs to directly address the underlying disease.

At Lamassu Biotech, we are working to change this.
👉 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕, our investigational molecule, is designed to target the root mechanisms of acute pancreatitis.

Because patients — and their clinicians — deserve more than supportive care.

11/06/2025

p53 is one of the most famous genes in oncology — often called “The Guardian of the Genome.”

But what does that actually mean? It depends on who you ask:
For patients → the cell’s emergency brake
For doctors → DNA repair & tumor suppression
For scientists → MDM2 regulation shapes p53 activity

𝐅𝐚𝐜𝐭: 𝐓𝐏𝟓𝟑 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐟𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐦𝐮𝐭𝐚𝐭𝐞𝐝 𝐭𝐮𝐦𝐨𝐫 𝐬𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐨𝐫 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 (~𝟓𝟎%).

What’s fascinating is how versatile p53 really is:
🧬 It’s not just about stopping damaged cells — p53 can trigger apoptosis, senescence, or even metabolic reprogramming, depending on the context.
📚 More than 90,000 scientific papers mention p53 — making it one of the most studied proteins in biology.
💊 Despite this, directly targeting p53 in drug development has been notoriously difficult (so-called “undruggable target”) — but new strategies like MDM2 inhibitors or p53 reactivators (e.g. APR-246/eprenetapopt) are showing promise.
⚡ A quirky fact: p53 wasn’t initially discovered as a tumor suppressor — early studies mistakenly thought it was an oncogene because of the mutant forms found in cancers.

In short → p53 is less of a single switch, and more of a network hub orchestrating the cell’s fate.

11/03/2025

Lamassu Biotech today announced a significant clinical milestone in its Phase 1/2a trial investigating SA53, a first-in-class, small-molecule MDM2 inhibitor. According to data reviewed to date, there have been no serious or dose limiting adverse events, and SA53 has thus far demonstrated a favorable safety and tolerability profile. The therapy is currently advancing into higher-dose cohorts for the treatment of adult patients with solid tumors.

The ongoing Phase 1/2a trial, conducted in collaboration with the National Institutes of Health (NIH) and Cleveland Clinic, is designed to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of SA53. The therapy is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options.

Read the full announcement here: https://www.lamassubiotech.com/2025/11/03/sa53-mdm2-inhibitor-lamassu-biotech-reports-significant-progress-and-favorable-safety-profile-in-phase-1-2a-clinical-trial/

Lamassu BioTech

01/12/2026

01/06/2026

12/30/2025

12/23/2025

12/23/2025

12/16/2025

12/11/2025

11/25/2025

11/17/2025

11/12/2025

11/06/2025

11/03/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category